Overview

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

Status:
RECRUITING

Trial end date:
2027-07-08

Target enrollment:

Participant gender:

Summary

This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag

Phase:

PHASE4

Details

Lead Sponsor:

Al-Mustansiriyah University

Treatments:

avatrombopag
Tablets